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Oxidative stress (OS) is considered as one of the etiologic factors involved in several signals and
symptoms of inﬂammatory bowel diseases (IBD) that include diarrhea, toxic megacolon and abdominal
pain. This systematic review discusses approaches, challenges and perspectives into the use of non-
traditional antioxidant therapy on IBD, including natural and synthetic compounds in both human and
animal models. One hundred and thirty four papers were identiﬁed, of which only four were evaluated in
humans. Some of the challenges identiﬁed in this review can shed light on this fact: lack of standardi-
zation of OS biomarkers, absence of safety data and clinical trials for the chemicals and biological mo-
lecules, as well as the fact that most of the compounds were not repeatedly tested in several situations,
including acute and chronic colitis. This review hopes to stimulate researchers to become more involved
in this fruitful area, to warrant investigation of novel, alternative and efﬁcacious antioxidant-based
therapies.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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Inﬂammatory bowel diseases (IBD) are most commonly re-
presented by Crohn's disease (CD), which involves any segment of
the gastrointestinal tract, and ulcerative colitis (UC), that occurs in
the inner lining of the colon (large intestine) or rectum. IBD is
characterized by chronic or relapsing immune activation andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Important risk factors associated with inﬂammatory bowel diseases and immunological changes.
F.A. Moura et al. / Redox Biology 6 (2015) 617–639618inﬂammation within the gastrointestinal tract [1]. The etiology of
IBD remains unclear but environmental factors, as well as in-
fectious, immunological, and psychological ones, together with
genetic susceptibility could be the major causes for the onset of UC
[2] (Fig. 1). Although the prevalence and incidence of IBD is in-
creasing (150–250/100,000 population), especially in developed
countries, it is rarely fatal. It can however, greatly diminish the
quality of life because of the pain, vomiting, diarrhea and other
socially unacceptable symptoms it causes. The increased risk of
colorectal cancer (from 0.5% up to 20% per year) is a serious
complication of IBD, particularly in the case of UC [3].
The current therapy for IBD relies on the use of sulfasalazine,
corticosteroids, immunosuppressive agents, such as azatriopine,
and biological therapy (Fig. 2) represented by the anti-TNFα (tu-
mor necrosis factor alpha) antibody as the mainstream treatment
for down-regulating aberrant immune responses and in-
ﬂammatory cascades [4]. However, the adverse effects associated
with these drugs over prolonged treatment periods and the high
relapse rate limit their use [5]. Sulfasalazine, for instance, can
exacerbate colitis, resulting in diarrhea, abdominal cramps and
discomfort [6]. Antibiotics, one of the commonly used therapies,
could adversely change the environmental conditions of micro-
biota and trigger resistance. Moreover, immunosuppressant and
anti-inﬂammatory drugs (such as corticosteroids) have many un-
desirable side effects [7] and the combined therapy, using corti-
costeroids plus inﬂiximab does not appear to provide any addi-
tional beneﬁt over inﬂiximab monotherapy [8]. Furthermore, these
drugs display limited beneﬁcial actions. In the long term, r25–
33% of patients with UC will require surgery if pharmacological
treatments are not successful, or in the case of complications such
as ﬁstulae, stenosis, or abscesses (particularly in Crohn's patients)
[9]. The potential of these drugs when used over a long period of
time, to induce severe side effects, together with the high costs of
the therapy for patients, warrant investigation of novel and al-
ternative pharmacological approaches [10].
In recent years, several studies had focused on reactive oxygen
species (ROS) and reactive nitrogen species (RNS) as the etiologic
factors for IBD [11–14]. The gastrointestinal tract is a major site forgeneration of pro-oxidants, whose production is primarily due to
the presence of a plethora of microbes, food ingredients and in-
teractions between immune cells [15]. Furthermore, the anti-
oxidant capacity of patients with IBD is reduced, even in the
asymptomatic phase of the disease [16]. To scavenge RONS, in-
testinal cells have several enzymatic and non-enzymatic anti-
oxidants, including superoxide dismutase (SOD), reduced glu-
tathione (GSH) and catalase (CAT), but excessive generation of
RONS enhances lipid peroxidation (LP) and could deplete anti-
oxidant defenses [17].
It should be noted that OS is clearly involved in IBD, once im-
mune activation such as inﬂammation [18] occurs and could be a
major contributing factor to tissue injury and ﬁbrosis that char-
acterize CD [19]. In this regard, reduction of plasma antioxidants
and total intestinal antioxidant capacity has been observed in CD
[20]. Like in CD, several studies have shown oxidative stress in UC.
Patients with UC often have antioxidant nutrient deﬁciencies at
the time of diagnosis [21–23] and that could suggest an increase of
OS.
In this context, recent studies have suggested that the admin-
istration of antioxidants, from different sources, with additional
anti-inﬂammatory action may be beneﬁcial in the treatment of IBD
because inﬂammation is caused by OS and leads to the increase of
OS that contributes to tissue damage [24–26].
Several reports on non-traditional therapy for IBD have been
published. However, those publications put special emphasis on
antioxidant and/or anti-inﬂammatory activity [25–27] or regula-
tion of gut microbiota [28, 29]. Unlike other published approaches,
this review is broader and aims to describe and analyze the effect
of functional foods and isolated nutrients, probiotics, natural ac-
tive compounds from vegetal sources, drugs, hormones and other
synthetic substances, all of them reported as antioxidants, in IBD.2. Methods
In 2009, Rahimi et al. [30] published a systematic review on the
use of herbal medicines for the treatment of IBD [31]. These
Fig. 2. Main substances used/tested in inﬂammatory bowel disease therapy (articles published from 2009–2015/06).
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and suggested their possible mechanisms of action. After that,
several reviews about this topic were published [25,26,32–38],
however, up to our knowledge, no one has so far discussed other
chemical strategies, applying antioxidants like drugs, polyphenolsand others in IBD treatment. In face of that, we reviewed the lit-
erature from 2009 up to 2015 (June) to in vitro and animal models
of colitis induction and without limit of time to human studies,
using the keywords inﬂammatory bowel disease or ulcerative
colitis or Crohn disease associated to antioxidant in the databases
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stances studied in vitro or in vivo (enemas, oral supplementation or
intraperitoneal application) were chosen. To minimize losses, the
search was conducted by two researchers, independently.
Initially, the titles of the papers were read, with exclusion of
duplicated articles. Thereafter, we identiﬁed if the reported work
had dealt with antioxidant action (OS biomarkers), using the fol-
lowing phrases:
(1) Scavenging of ROS/RNS ⇒ decrease of the levels of nitrite,
nitric oxide (NO), superoxide anion (O2–), hydrogen peroxide
(H2O2) and others;
(2) Inhibition of RONS synthesis ⇒ decrease of the activity, pro-
tein expression or genic expression of inducible nitric oxide
synthase (iNOS), cyclooxygenase 2 (COX2), NADPH oxidase
(NOX), lipoxygenase (LOX), myeloperoxidase (MPO), nuclear
factor Kappa-light-chain enhancer of activated B cells (NF-κB)
or Iκ-Bα (nuclear factor of kappa light polypeptide gene en-
hancer in B-cells inhibitor, alpha);
(3) Inhibition of RONS damage ⇒ biomarkers of LP (thiobarbituric
acid reactive substances (TBARS), malondialdehyde (MDA),
4-hydroxynonenal (HNE) and others), protein damage (protein
carbonylation, advanced glycation end-products (AGE) and
others) and deoxyribonucleic acid (DNA) damage (8-oxo-2′-
deoxyguanosine, 8-oxoguanine and others);
(4) Increase of antioxidant defense (endogenous enzymatic and
non enzymatic antioxidant defense and total antioxidant
capacity).
Thereafter we categorized the therapies into topics, as
following:
(a) Drugs, hormones, synthetic antioxidants and chemicals de-
rived from sources, other than vegetables;
(b) Polyphenols and other natural active compounds from med-
icinal plants;
(c) Functional foods, antioxidant nutrients and probiotics.Fig. 3. Main results from the database search.3. Results and discussion
One-hundred and thirty four papers were found. A summary of
the method and the total number of articles for each category are
displayed in Fig. 3.
In sequence, we will discuss the role of OS in IBD, the major
biomarkers used in diagnosis, and the several classes of anti-
oxidants available for IBD treatment.
3.1. Oxidative stress and IBD
OS is deﬁned as an imbalance between oxidants (ROS, RNS) and
antioxidants in favor of the oxidants, leading to a disruption of
redox signaling and control and/or molecular damage [39]. ROS is
generally taken to encompass the initial species generated by
oxygen reduction as well as their secondary reactive products, and
include free radicals such as the radical anion superoxide O2 ,
hydroxyl radical (HO), peroxyl (RO2), alcoxyl (RO) and hydro-
peroxyl (HO2), and non-radical species such as singlet oxygen
(1O2), H2O2 and hydrochlorous acid (HOCl). RNS include free ra-
dicals like nitric oxide (NO), nitrogen dioxide (NO2), anions like
peroxynitrite (ONOO–), as well as nonradicals such as nitrous
oxide (HNO2), nitryl chloride (NO2Cl) and alkyl peroxynitrites
(ONOOR) [40].
Gastrointestinal (GI) tract is a key source of ROS production.
Despite the protective barrier provided by the epithelial layer,
ingested materials and pathogens can cause inﬂammation byactivating the epithelium, polymorphonuclear neutrophils (PMNs),
and macrophages to produce inﬂammatory cytokines and other
mediators that contribute further to OS [41].
Dysfunction of the intestinal barrier accompanied by increased
intestinal permeability is another characteristic symptom in the
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commensal bacteria to adhere to the epithelial layer via oligo-
saccharides helps deter invasion by displacing pathogenic bacteria
[43]. In this context, the increased permeability of gastrointestinal
epithelial cells frequently results from the destruction of tight
junctions (TJ), and release of different pro-inﬂammatory media-
tors, including ROS and RNS, which actively contribute to the pa-
thogenic cascade that initiates and perpetuates the inﬂammatory
response in the gut [44].
The main sites of RONS production in IBD are activated neu-
trophils and macrophages. During episodes of inﬂammation, these
cells exhibit massive intestinal mucosa inﬁltration and release
large amounts of these species [45]. The enhanced production of
RONS is associated with chronic intestinal inﬂammation in the
early stages of IBD, and their destructive effects on DNA, proteins
and lipids may contribute to initiation and progression of CD [19]
as well as UC [46], resulting in prominent inﬂammation, increased
amounts of cytokines such as tumor necrosis factor (TNF)-α, in-
terleukins IL-6 and IL-1β. Such biological compounds trigger the
pathological responses and symptoms of IBD [47]. The increased
OS associated with peripheral DNA damage may be one of the
pathophysiological mechanisms in the development of UC asso-
ciated colorectal cancer, together with actin carbonylation and
nitration of actin and tubulin which disrupt the cytoarchitecture
and cause tissue injury [48].
Another factor involved in the etiology of colitis is the enzyme
Glutathione Peroxidase type 2 (GPx2), a gastrointestinal-speciﬁc
form of GPx. According with a recent review, in contrast to other
enzymes such MnSOD and CAT, which had been shown to be
modestly reduced in inﬂamed issue, GPx2 had its expression in-
creased during colitis [49]. An in vitro investigation with tissue of
patients with colorectal cancer or UC, had identiﬁed that GPx2 is
strategically located in endoplasmic reticulum where it can inter-
fere with COX-2 activity by local removal of hydroperoxides and,
thus, regulates the level of prostaglandin E 2 (PGE2), considered to
be a key mediator of acute inﬂammatory responses [50]. The re-
levance of the hydroperoxide level to inﬂammatory processes in
the gastrointestinal system is indeed evident from the sponta-
neous development of ileocolitis and intestinal cancer in GPx1/2
DKO mice. In this case, a synergism between both enzymes is
suggested, but the role of GPx2 appears to be more important,
since a single allele of GPx2 but not of GPx1 proved to be sufﬁcient
to prevent inﬂammation in this knockout mice [51]. Therefore,
GPx2 activation may prevent undue responses to inﬂammatory
stimuli and, in consequence, inﬂammation-driven initiation of
carcinogenesis
A summary of these alterations is displayed in Fig. 4. In brief,
RONS cause intestinal tissue lipid peroxidation, necrosis/apoptosis
and epithelial ulcers. These species are also responsible for the
disruption of intercellular junctions, as well as leukocyte and
neutrophil inﬁltration that produce ROS, RNS and cytokines that
lead to the inﬂammatory process. Nitric oxide (NO) acts on
chloride anions and stimulates their release into the intercellular
medium with a consequent loss of water leading to osmotic diar-
rhea. NO also diffuses into the muscle layer and can cause toxic
megacolon, a common complication of IBD, especially in the case
of UC.
To regulate the destructive effects of RONS, vital tissues are
equipped with an intricate antioxidant defense system. These
antioxidant control systems consist of enzymes such as SOD, CAT,
GPx and peroxiredoxins [52], as well as antioxidant compounds,
like α-tocopherol, β-carotene, vitamin C, GSH, bilirubin, urate,
zinc, selenium and copper [53]. When this system fails, OS occurs
[12]. Increased formation of RONS in the colonic mucosa in animal
models of IBD has been known to be correlated not only with
disease severity and progression, but also with extra-intestinalmanifestations of UC, such as hepatobiliary disorder [54].
Inhibition of both inﬂammatory mediators and ROS production
would provide an important protective and therapeutic treatment
for IBD [47,55,56]. Therefore, identifying new antioxidants for IBD
treatment has recently attracted much attention worldwide and
will be discussed below.
For instance, some authors observed no difference [57], de-
creased [58] or increased levels [14], in plasma/erythrocyte, of
antioxidant enzymes in patients with active intestinal inﬂamma-
tion. In a study [16], the authors showed signiﬁcant modiﬁcations
regards levels of OS markers in the serum of patients with active
IBD, such as decreased SOD and GPx activity, and a low antioxidant
proﬁle and increased lipid peroxidation in patients in the remis-
sion phase. In tissue biopsies, an increase of malondialdehyde
(MDA) was found, in both UC and CD patients [59] and reduced
GPx and glutathione (GSH) activity/levels in inﬂamed CD mucosa
[60]. A possible explanation given by the authors for low GPx and
SOD in remission patients is the consumption of antioxidants
present in the diet or supplementation during active phases. An-
other and more tempting hypothesis is that the patients suffering
from IBD, even if they are in remission, have a low antioxidant
defense, i.e. a pre-existing redox imbalance condition [18].
Despite the difﬁculty of comparing antioxidant capacity, due to
the use of different methods, single versus chemical products in
mixture, one table, listing chemicals, pure and in mixture, func-
tional foods, and others, is herein included and the main bio-
markers of OS analyzed (see Table 1). There are several con-
troversies and contradictory results, which point out to the ne-
cessity of further experimental research.
The relationship between colitis and cancer is also associated to
activation of common tumor-related signaling pathways, including
mutations of the p53 gene, the most frequently reported somatic
gene alterations in human cancer, leading to accumulation of p53
gene products in tumor cells that can initiate an immune response
with generation of circulating anti-p53 antibodies (p53Abs) [61].
Several studies have demonstrated that p53 overexpression is
found in IBD patients and this fact is closely associated with
neoplasia, especially in those with mucosa dysplasia [62]. The p53
activation is intrinsically associated with OS, by inducing the ex-
pression of p85, which may function as a signaling molecule
during ROS-mediated p53-dependent apoptosis. p85 is a known
regulator of phosphatidyl inositol-3 kinase (PI3K); however, its
function during ROS-induced apoptosis is independent of PI3K
[63]. p53 also induces NO– cellular stress, and chronic in-
ﬂammation, as well as elevated levels of the inducible nitric oxide
synthase (iNOS) and increased TP53 mutation [64]. Staib et al. [65]
identiﬁed 14 common genes among NO, H2O2, DNA replication
arrest, and hypoxia, and interestingly 8 of them are known as p53
target genes [65].
3.2. Oxidative stress biomarkers
As previously mentioned, OS is a crucial pathophysiological
factor for human IBD. It is therefore important to identify the best
biomarkers for the diseases, in order to verify whether the applied
therapy is effective or not, in controlling the symptoms of IBD.
Antioxidant enzymes such as SOD, GPx and CAT, and the non-
enzymatic sulfhydryl groups play a major role in the organism
defense against excess RONS generation, but changes in this pro-
ﬁle seem to be the most difﬁcult to quantify when looking at the
various studies done on IBD. In fact, the identiﬁcation of OS bio-
markers is an important challenge to the scientiﬁc community as
well as the analysis of the sensitivity of these biomarkers in the
several biological matrixes (urine, blood, and tissue etc.) and how
analytical procedures can compare, appropriately, each of these
biomarkers [66].
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[59], and for that, MDA or thiobarbituric acid reactive substances
(TBARS), an indirect measure of MDA, is extensively used as a
biomarker for oxidative damage. However, because other biologi-
cal materials may react with thiobarbituric acid, resulting in high
TBARS levels, this marker is under scrutiny. Other molecules de-
rived from LP, such as hydroperoxides, isoprostanes, conjugated
dienes and others have been used by the scientiﬁc community, but
like MDA, have advantages and limitations [67]. Among these
molecules, F2-isoprostane, measured by mass spectrometry, has
been the best general indicator of non-enzymatic lipid peroxida-
tion under normoxic conditions [68]
Myeloperoxidase (MPO), a heme protein secreted by phago-
cytes, especially neutrophils, is a marker for local leukocyte se-
questration and inﬂammation. An increase in MPO activity and the
generation of NO has also been demonstrated in inﬂamed colon
biopsies and both are related to the disease's progression [69].
Reports have demonstrated a signiﬁcant correlation with other OS
markers, such as MDA and H2O2, in patients with metabolic syn-
drome [70]. In bowel, MPO is present in neutrophils and macro-
phages derived from inﬂamed mucosa inﬁltration in the damaged
area and rupture of the colonic barrier. They produce both in-
ﬂammatory mediators (cytokines and chemokines) and OS
through the generation of HOCl and oxidation of the unsaturated
fatty acids present in the plasma membrane [71] (Fig. 4). Fur-
thermore, MPO levels are found to be elevated in malignant tis-
sues, suggesting that MPO-derived oxidants play a role in colon
cancer [72].
For Hartmann, besides lipid peroxidation, the increase of iNOS
expression and consequently NO levels in rats, was associated
with a signiﬁcant decrease in anal sphincter pressure [73] and
consequent increased diarrhea and other IBD symptoms.Fig. 4. Oxidative stress and its association with the physiopathological process of IBD.
Legend description: reactive oxygen species (ROS) are produced through several meta
transport chain normally transforms 2–3% of O2 to O2– (complex I and III). Then, this
cytosol, O2– can be generated by (3) xanthine oxidase (XO), (4) cyclooxygenase 2 (COX2
(AGE) that are involved with the inﬂammatory process, or can form (7) H2O2 by CuZn
lymphocytes and (A) neutrophils (principally), coming from leukocyte inﬁltration that is
highly biomembrane permeable, facilitated by the (9) aquaporin-8 channel. In the cytoso
and Haber-Weiss reactions, H2O2 forms the hydroxyl radical (HO  ) which is highly toxic
DNA fragmentation, (13) inactivation of mitochondrial pyruvate dehydrogenase (PDH),
These damaging actions cause (11) tissue disruption and cellular death and then ulceratio
mitochondrial O2– generation and OS, which has a direct relationship to the severity o
bacterial translocation, which stimulates macrophages and neutrophil recruit, as well a
inﬁltration, causing inﬂammation. Another enzyme present in the cytosol, lipoxygenase
All reactive nitrogen species (RNS) are formed from nitric oxide (NO), produced by (18) i
reacts with O2– to furnish (19) the peroxynitrite anion (ONOO–), which then becomes (
nitrogen dioxide (NO2) that causes LP. ONOO– is highly reactive and can cause (12) D
actions on enterocytes. This gas stimulates (22) chloride secretion to the mucosa with a co
most frequent symptom of IBD. RNS are chemotactic mediators of macrophages and n
tracellular environment. Nitric oxide, despite having a half-life of ≅ 3 s, can (26) diffuse
relaxing and consequently toxic megacolon, a common clinical complication of IBD.
Because of disrupted permeability, antigens derived from food digestion and from com
provoke a continuous intestinal immune response that then causes tissue damage. The
erosions and ulcerations leading to an increased exposure to intestinal microbiota and
Antioxidant cell defenses involve enzymes and non-enzymes present in peroxisomes. I
principally in the inﬂammatory process, and (28) by glutathione peroxidase (GPx). For pe
oxidized form (GSSH). For regeneration of GSH, the presence of (29) glutathione reduct
Adapted from Refs. [46,71,132].
A – Disruption of intercellular junctions
The intercellular junctions of the intestinal epithelium are constituted of tight junctions
barrier to the entry of allergens, toxins and pathogens across the epithelium into the in
ONOOH cause nitration of actin present in the cell cytosol. Concomitant to RNS, H2O2 a
of occludin – connected to actin by ZO (Zonula occludens) (1, 2 or 3) proteins – and phos
this to actin. Both, actin rearrangement (caused by nitration) and (de)phosphorylation
dysfunction and consequent increase of intestinal permeability to neutrophil and bacte
B – Neutrophils and OS
Neutrophils are the principal ROS and RNS sources during the inﬂammatory process. The
the myeloperoxidase (MPO) enzyme, which leads to the production of hypochlorus acid
Adapted from Refs. [19,71].Furthermore, these compounds cause damage to cells of the mu-
cosa and submucosa of the bowel [74]. iNOS is represented by
three isoforms of NOS and is found in macrophages and smooth-
muscle cells. It allows the production of NO in large quantities as
part of the mechanism of cell death in response to lipopoly-
saccharides, cytokines, and glucocorticoids. As such, this enzyme
and its metabolites are involved in septic shock and inﬂammatory
disorders [75].
Another common metabolite, GSH, has been used as an alter-
native indicator of both inﬂammation and OS, once its intracellular
levels suffer modiﬁcation due to its action in the extracellular pool,
which is related with its function in detoxiﬁcation and protection
of cells from chemical- and oxidant-induced injuries [76]. In in-
ﬂammatory diseases, for instance, the rate of consumption of GSH
may increase dramatically [77]. For IBD subjects, contradictory
results have been reported in terms of both GSH levels and GSH/
GSSG ratio. In colon biopsies, either a decrease [78] or no changes
in GSH levels [79], along with an increase in GSSG levels [78] had
been detected. In fact, in animal colitis models, GSH levels are
normally reduced [80–82].
According to Sakthivel et al. [83], SOD levels increase in UC
induced by intrarectal acetic acid. The elevation of SOD and other
antioxidants can be explained by the fact that in IBD, inﬂammation
and OS are present and this SOD increase would protect the tissue
against oxidative damage. However, in studies on UC induced by
acetic acid [82,84] and TNBS [81,85,86], SOD activity was reduced,
which clearly indicates increased levels of OS, which may damage
cells through lipid peroxidation of membranes and oxidation of
cellular proteins [84]. Similar results were observed for GPx. Ac-
cording to Rabelo Socca et al [81] and [87], GPx activity in rats
with UC induced by TNBS, increased, whereas for Mueller et al., in
a DSS (dextran sulfate sodium) UC model, this enzyme activity wasbolic pathways. (1) In mitochondria, during the respiratory process, the electron
reactive species undergoes dismutation by Mn-SOD and generates (2) H2O2. In the
) and (5) NADPH oxidase (NOX) and generates (6) advanced glycation end-products
–SOD. Hydrogen peroxide can be also produced by (8) immune cells: monocytes,
characteristic of IBD. The reactive molecule H2O2, unlike the O2–, is long lived and
l, together with metals such as Fe2þ , Cu2þ , Co2þ and Cr2þ , and by (10) the Fenton
and can directly cause (11) lipid peroxidation (LP). Other actions by HO are: (12)
(14) mucin depolarization and (15) destruction of (B) apical intercellular junctions.
ns in the mucosa, typical IBD damage; (12) mutagenesis and cancer; (13) increased
f the disease; (14) decreased formation of the mucous layer and promotion of (15)
s increased intestinal permeability; and facilitates (16) leukocytes and neutrophil
(LPO) also causes LP via (17) lipoperoxide (LOOH) formation.
nducible nitric oxide synthase (iNOS) that converts L-arginine to L-citruline. The NO
20) peroxynitrous acid (ONOOH). The latter then generates the new species (21) of
NA fragmentation and RNS/ROS stimulation (10) of LP. Nitric oxide has dangerous
nsequent (23) water release into the intestinal lumen causing osmotic diarrhea, the
eutrophils that (24) stimulate ferrous release from defense cells (25) into the in-
to the muscle layer (smooth muscle) and causes no-cholinergic and no-adrenergic
mensal or pathogenic bacteria can overcome the unprotected mucosal barrier and
inﬂammatory response often results in continued epithelial injury, which causes
ampliﬁcation of the inﬂammatory response.
n this organelle, H2O2 can be transformed into water (H2O) by (27) catalase (CAT),
roxisomes to obtain GPx there is a need to convert reduced glutathione (GSH) to its
ase (GR) – glutathione cycle is necessary.
(TJ), adherent junctions (AJ), and desmosomes. The epithelial tight junctions form a
terstitial tissue. ROS and RNS can promote disruption of both, TJs and AJs. NO  and
nd HO can cause dephosphorylation (serin/thyrosin) or phosphorylation (thyrosin)
phorylation (tyrosine) of β-catenin – which connect E-cadherin with α-catenin and
of adherent/linker proteins, promote disruption of intercellular junctions, barrier
rial/toxin inﬁltration and hence the inﬂammatory processes.
se cells produce O2– from NOX and NO from iNOS. H2O2 and Cl- are produced by
(HOCl). Both MPO and HOCl cause LP and tissue damage.
Table 1
Compounds and mixtures of compounds with antioxidant effects tested in inﬂammatory bowel disease: articles published from 2009–2015/06.
Compounds Molecular mechanism/ plant
origin
Refs Antioxidant action
↓RONS ↓ RONS synthesis ↓ RONS damage Improved antioxidant defense
NO ROS iNOS COX2
LPO
NOX
MPO NF-
κB
/Iκ-
Bα
LP PTN DNA SOD CAT GPX GR
GSH
GST
Nrf2 AOC
Drugs
Telmisartan Angiotensin II receptor
antagonist
[99] X X X X X X X X X
[100] X X
Olmesartan [251] X X X
Rivastigmine Cholinergic agent [252] X X
Aminoguanidine Selective iNOS inhibitor [154] X X X
Sildenaﬁl citrate (Viagra) Therapy for erectile dysfunc-
tion terase
[253] X X X
[254] X X X
Setarud (IMOD) Immunomodulator [167] X X X
Carvedilol Nonselective β-adrenoceptor
blocker
[255] X X X X X X X
Spironolactone Aldosterone receptor
antagonist
[256] X X X
Fluvoxamine Selective serotonin reuptake
inhibitors
[257] X
Fc11a-2 (1-ethyl-5-me-
thyl-2-phenyl-1H-
benzo[d]imidazole)
– [258] X
Sinvastatin Inhibitor of hydro-
xymethylglutaryl COA
reductases
[101] X X X X
Rosuvastatin [101] X X X X
Amlodipine Calcium channel blockers [259] X X X
Lazaroid U-74389G Nonglucocorticoid analogs of
methylprednisolone
[260] X X X
Hormones
Melatonin Sleep metabolism [104] X X X X X X
[96] X X X X
[234] X X
[109] X X
[108] X
Ghrelin Stimulation of appetite and
gastrointestinal motility
[261] X X X
Adrenomedullin Gastrointestinal peptide [262] X X X
Synthetic compounds
N-acetylcysteine (NAC) [120] X X X X X
[235] X X X
[236] X
[237] X X X X
[238] X X X X
Bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)
decandioate
[239] X
[240] X X
3,4-Oxo-isopropylidene-shikimic acid (ISA) (derivative of
shikimic acid (Illicium verum Hook))
[241] X X X X
[242] X X X X X X X
[243] X X X X X X
3-(3-Pyridylmethylidene)-2-indolinone [93] X X
Chito-oligosaccharides [263] X X X X
Peptide P-317 [264] X
Chemicals derived from sources other than vegetals
Superoxide dismutase recombinant Lactobacillus
fermentum
[126] X X X X
Lecithinized superoxide dismutase [124] X X
Lipoic acid [55] X X X X X X
Citicoline [265] X X X
Propionyl-L-carnitine [128] X X
Butyrate, Lactobacillus casei, and L-carnitine [266] X X X
Methylsulfonylmethane (dietary supplement) [267] X X X X
Spirulina (dried biomass of Arthrospira platensisa-
microalgae)
[248] X
[247] X X X X X
Dunaliella salina (microalgae) [247] X X X X X
Aspergillus nidulans (fungus) [268]
Inonotus obliquus (fungus) [269] X X
Ursodeoxycholic acid (secondary bile acid) [270] – – –
Polyphenols
Colon speciﬁc resveratrol [137] X
Trans Resveratrol [138] X
[244] X X X X
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Table 1 (continued )
Compounds Molecular mechanism/ plant
origin
Refs Antioxidant action
↓RONS ↓ RONS synthesis ↓ RONS damage Improved antioxidant defense
NO ROS iNOS COX2
LPO
NOX
MPO NF-
κB
/Iκ-
Bα
LP PTN DNA SOD CAT GPX GR
GSH
GST
Nrf2 AOC
[140] X
Resveratrol [142] X X
[135]* X
[141] X X X X
[143] X X
Piceatannol (hydroxylated analog of resveratrol) [143] X X
Caffeic acid [271] X
4-Vinyl-2,6-dimethoxyphenol (canolol) [11] X X X X
Verbascoside [272] X X X
Ellagic acid [273] X X X X
[274] X X X
β-Sitosterol, campesterol, stigmasterol and brassicasterol [32] X
Curcumin [151] X X X X
[152] X X X X X
[153] X X
[154] X X X
Coumarin [246] X X X X
[76] X X X
[245] X X
Apple polyphenols extract [275] X
Green tea polyphenols [276] X
Epi-gallocatechin-3-gallate plus 1-piperoylpiperidin
(piperine)
[277] X X
Piperine [278] X X X X X
Peracetylated epi-gallocatechin-3-gallate [163] X X X
Epi-gallocatechin-3-gallate [279] X
Proanthocyanidins from grape seeds [165] X X
[166] X X X X
[85] X X X X
Quercetin [155] X X X
[156] X X X
[280] X X X X
Diplacone [281] X X X
Mimulone [281] X
Amentoﬂavone [83] X X X X X
Myricetin [172] X X X X X
Naringenin (4,5,7-trihydroxyﬂavonone) [170] X X X X
Kolaviron [171] X X X X X X
3′-Hydroxy-5,7,4′-trimethoxyﬂavone from Zeyheria
montana
[282] X X
Other natural active compounds of medicinal plants
Thymoquinone Nigella sativa [283] X X X
Sesamol (phenolic
derivate)
Sesamum indicum [284] X X X
Indicaxanthin (pigment) Opuntia ﬁcus-indica [177] X X X X X
Ginsenoside Rd Panax notoginseng [285] X X X X X
Iridoid glycosides Folium syringae [286] X X X X
Embelin (quinone) Embelia ribes [287] X X X
[288] X X X
Sanguinarine (alkaloid) Sanguinaria canadenses and
Argemone mexicana
[289] X X
Taurohyodeoxy-cholic
acid
Pulvis fellis suis [290] X
Berberine (alkaloid) Coptidis japonica and Mahonia
aquifolium
[178] X X X X X X X
Cannabigerol Cannabis sativa [179] X X X X X
Cannabidiol [180] X X X X
3,3′-Diindolylmethane Brassica [291]
Flavanolignan Sylmarin (Silybum
marianum)þSelenium
nanoparticles
[292] X X X X X X
Aloin (anthraquinone)
Aloesin (chromone)
Aloe vera Aloe-gel [293] X
Oligonol 17.6% of catechin-type mono-
mers and 18.6% of proantho-
cyanidin dimers and trimers
[294] X X X X X X
Cavdina Corydalis impatiens [295] X X X X X
Fraxinellone (lactone) Cortex dictamni [296] X X X X
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Table 1 (continued )
Compounds Molecular mechanism/ plant
origin
Refs Antioxidant action
↓RONS ↓ RONS synthesis ↓ RONS damage Improved antioxidant defense
NO ROS iNOS COX2
LPO
NOX
MPO NF-
κB
/Iκ-
Bα
LP PTN DNA SOD CAT GPX GR
GSH
GST
Nrf2 AOC
Asiatic acid (triterpenoid
compound)
Centella asiatica [297] X X
Isatin (1H-indole-2,3-
dione)
Heterocyclic compounds
found in various medicinal
plant species
[81] X X X X X
Allicin Garlic [298] X X X X X X X
Functional food and nutrients
Camel's milk [31] X X X
Extra virgin olive oil diet enriched with hydroxytyrosol
(polyphenol)
[199] X X X X
[195] X X
[188] X X
[299] X X X
[300] X X X X
[301] X X
Vitamin E [47] X X X X
Selenium and vitamin E [209] X X X
Vitamin C, vitamin E, and glutathione [210] – – – X
L-arginine and gallic acid [302] X X X X X
Anti TNFαþzinc acetate [214] X
Coenzyme Q10 [259] X X X
Lacto-wolfberry (formulated product of wolfberries in
skimmed milk)
[303] X X X X X
Vitamins C and E [215]* X
Vitamin C, vitamin E, β-carotene, zinc, selenium and
glutamine
[216]* – –
Probiotics
Recombinant probiotic [230] X# X#
Modiﬁed Lactobacillus casei BL23 strains [220] X X
L. delbrueckii subsp. bulgaricus B3 strain; L. delbrueckii
subsp. bulgaricus A13 strain
[227] X X X X X
Lactococcus lactis subsp. cremoris FC [304] X X
Ultrabiotiques (Lactobacillus acidophilus, Lactobacillus
plantarum, Biﬁdobacterium lactis and Biﬁdobacterium
breve).
[228] X
Lactobacillus fermentum [229] X
TR5 (Streptococcus thermophilus, Lactobacillus reuteri, Bi-
ﬁdobacterium biﬁdium, Latobacillus acidophilus, and La-
tobacillus casei)
[305] X X X X X X X
Lactobacillus pentosus var. plantarum C29 [306] X X X X X X
Lactococcus lactis [307] X X
Ultrabiotiques (L. acidophilus, L. plantarum, B. lactis and B.
breve)
[308] X X X
Lactobacillus plantarum 21 [309] X X X
Butyricicoccus pullicaecorum [310] X
AOC¼antioxidant capacity; CAT¼catalase; COX2¼cyclooxigenase type 2; DNA¼deoxyribonucleic acid; GPx¼glutathione peroxidase; GR¼glutathione reductase;
GSH¼glutathione; GST¼glutathione S-transferase; iNOS¼ inducible nitric oxide synthase; Iκ-Bα¼nuclear factor of kappa light polypeptide gene enhancer in B-cells in-
hibitor, alpha; LP¼ lipid peroxidation; LPO¼ lipoxygenase; MPO¼myeloperoxidase; NF-κB¼Nuclear Factor Kappa-light-chain-enhancer of activated B Cells; NO¼nitric
oxide; NOX¼nicotinamide adenine dinucleotide phosphate-oxidase; Nrf2¼nuclear factor erythroid 2; PTN¼protein; Refs¼references; RONS¼reactive oxygen and nitrogen
species; ROS¼reactive oxygen species; SOD¼superoxide dismutase. –¼ did not alter; * human study; #clinical studies, in human beings
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The recognition of ROS/RNS and redox-mediated protein
modiﬁcations as transducing signals has opened up a new ﬁeld in
cell regulation and provided a novel way of controlling disease
processes. Such approach has been proven feasible for gene ex-
pression governed by the transcription factor NF-κB [89]. This
mediator is activated when membrane cell receptors, such as in-
terleukine 1 beta (IL-1β), TNF receptor 1 (TNFR1), nicotinamideadenine dinucleotide phosphate-oxidase (NOX) and toll-like re-
ceptors type 4 (TLR4) promote the phosporylation of its NF-κB
inactive form (IκBα). After entry into the nucleus, NF-κB stimu-
lates pro-inﬂammatory, pro-oxidant and pro-apoptotic genes, for
instance, COX2 (cyclooxygenase 2), iNOS, caspases and others [90].
Still in the ﬁeld of transcription factors, another anti-in-
ﬂammatory mediator, nuclear erythroid 2 factor (Nrf2), is emer-
ging as an important OS biomarker. When activated for
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attenuation of phosphorylated IκB and, in consequence, NF-κB
degradation [91]. Nrf2 also stimulates activation of over two dozen
genes involved in antioxidant and anti-inﬂammatory activities
such as antioxidant response element (ARE), NAD(P)H quinone
oxidoreductase-1 (NQO-1), heme oxygenase-1 (HO-1), peroxir-
edoxin 1, γ-glutamylcysteine ligase, GPx, and glutathione disulﬁde
reductase [92]. Nrf2/ mice had been used successfully in ex-
perimental model of colitis, conﬁrming the closely role of this
nuclear factor in bowel inﬂammation [93].
However, more recently, some results have brought doubts
about the antioxidant and anti-inﬂammatory role of Nrf2. Kathiria
et al. [94] identiﬁed an important effect of the prohibitin 1, a
protein which regulates cell cycle progression, apoptosis, and
transcription factor activity. It was shown to be decreased in
mucosal biopsies from UC- and Crohn's disease-afﬂicted patients
and in animal models of colitis. According to these authors, this
protein maintained increased ARE activation and decreased in-
tracellular ROS levels and increased colonic levels of the anti-
oxidants HO-1 and NQO-1 via a mechanism independent of Nrf2.
On the other side, [95] discovered a pro-oxidant action by Nrf2 via
induction of transcription Kruppel-like factor 9 (Klf9) and further
cell death.
Therefore, several agents, in special, dietary compounds, are
used to modify or modulate molecular targets such as oxidative
and or inﬂammatory markers, with the objective of prevention/
amelioration of UC [37].
Thus, these results conﬁrm the need for more investigations
regarding redox proﬁles and markers in both states of health and
disease. A summary of some biomarkers of OS found in this review
is displayed in the Graphic Abstract.
3.3. Antioxidant therapy
When the antioxidant capacity of the damaged mucosa is
compromised, the use of nontraditional therapy such as drugs,
hormones, natural or synthetic substances and live organisms that
eliminate RONS, inhibit cell damage (LP, protein and DNA mod-
iﬁcation) and improve the activity of antioxidant enzymes, can be
beneﬁcial, either associated or not with anti-inﬂammatory medi-
cines [74]. Thus, agents that can target multiple molecular path-
ways, have fewer side effects, and are less expensive have en-
ormous potential in the treatment of UC, with reduction of its
severity, and in consequence, lead to a decrease in systemic da-
mage [96].
3.3.1. Drugs, hormones, synthetic compounds and chemicals derived
from sources other than vegetables
Pharmacological treatment of IBD attempts to minimize the
symptoms associated with structural and functional abnormalities
of the mucous membranes [23]. Current therapy includes corti-
costeroids and immunosuppressive agents (Fig. 2) and can cause
serious adverse effects such as gastrointestinal problems (diarrhea,
cramping, and abdominal pain), anemia, carcinogenesis, hepato-
toxicity, nephrotoxicity and hypersensitivity reactions [97]. An-
other important observation refers to low or no response of some
people to these medications [74].
3.3.1.1. Inhibitors of angiotensin II type 1. Among the studies eval-
uated in this review, the angiotensin II (Ang II) receptor antago-
nists (telmisartan and olmesartan – Fig. 2) have been shown to
have beneﬁcial outcomes (Table 1). These drugs act on angiotensin
II type 1 (AT1) receptors, and as such, decrease angiotensin II ac-
tion. This peptide promotes tissue inﬂammation through up-reg-
ulation/activation of NADPH oxidase with consequent generation
of O2– and causes activation of NF-kB, with sequential productionof pro-inﬂammatory cytokines, chemokines, growth factors, and
adhesion molecules, which cause inﬂammation and ﬁbrosis [98].
Among several candidates as Ang II receptor blockers (ARBs) such
as valsartan and olmesartan, telmisartan (TLM) (Fig. 2) was the
only one with anti-inﬂammatory and antioxidant characteristics. It
blocks Ang II AT1 receptors and is a partial agonist of peroxisome
proliferator-activated receptor-gamma (PPAR-γ), a nuclear tran-
scription factor that plays a role in the regulation of carbohydrate
and lipid metabolism, and suppresses inﬂammatory gene expres-
sion, with this effect being independent of the blood pressure-
lowering effects induced by AT1 receptor antagonism, thus
showing a marked protective effect on colitis [99].
According to Arab et al. [99], oral treatment with telmisartan
(TLM) in rats (10 mg/kg bw/d for 1 week before induced colitisþ4
days after induced colitis) suppressed ROS generation by inhibition
of NF-kB/p65, COX2 (cyclooxygenase type 2) and iNOS mRNA ex-
pression, as well as NF-kB/p65 protein colonic expression. Other
antioxidant actions attributed to TLM were suppression of lipid
peroxidation, scavenging of NO, increasing of GSH levels, of total
antioxidant capacity (TAC), and of SOD and GPx activity [99]. In a
study by Guerra et al., they evaluated the use of TLM (1, 3, and
5 mg/kg bw/d) orally for 3 days before induction of UC in rats and
also 2 and 24 h after induction, which showed that a dose of 5 mg/
kg reduced colonic MPO activity and colonic levels of MDA [100].
These ﬁndings highlighted the beneﬁcial effects of TLM for the
treatment of IBD, which is mediated through modulation of co-
lonic inﬂammation and OS (Table 1).
3.3.1.2. Inhibitors of hydroxymethylglutaryl COA reductases. The
drug class called statins, in this review represented by simvastatin
and rosuvastetin (Fig. 2), studied by Maheshwari et al. [101] pre-
sented an important antioxidant effect, represented by inhibition
of MPO activity, decrease of lipid peroxidation and increase of SOD
and GR activity in rats. The interest to test this class in UC is re-
lated to its anti-inﬂammatory and endothelial cell protective ac-
tions, independent of their antihyperlipidemic effects [102]. Be-
sides attenuating OS, these drugs, especially simvastatin, also im-
prove histologic parameters in TNBS-induced colitis in rats.
3.3.1.3. Hormones. Another nontraditional therapy, successfully
tested on IBD, is hormone therapy, speciﬁcally melatonin (MEL)
(Fig. 2). Chemically, MEL or N-acetyl-5-methoxytryptamine is a
derivative of the essential amino acid tryptophan. In the gastro-
intestinal tract (GI), MEL comes from both pineal melatonin and de
novo synthesis within the GI tract. It may have a direct effect on
many GI tissues, serving as an endocrine, paracrine, or autocrine
hormone, inﬂuencing the regeneration and function of epithelium,
modulating the immune milieu in the gut, and reducing GI muscle
tonus by targeting smooth muscle cells [103]. There is a large body
of evidence depicting the protective effect of MEL in various ex-
perimental and clinical conditions [104]. It plays an important role
as a regulator of inﬂammation, as well as in proper immune sys-
tem and antioxidant system function for intestinal disorders [105].
In animal experiments, MEL administration was shown to have
anti-inﬂammatory action through inhibition of IL-10, IFN-γ, TNF-α,
IL-6, and NO. As such, MEL also shows antioxidant properties
such as free-radical scavenging; reduction of HO, ONOO-, RO2
and singlet oxygen levels [106]; inhibition of COX2 expression and
NF-kB activation [107] and iNOS expression [108]; and increase of
Nrf2 (nuclear factor erythroid 2) expression [104], which is a nu-
clear mediator for anti-inﬂammatory and antioxidant genes. All
these results suggest that MEL may exert beneﬁts on UC by re-
ducing or controlling inﬂammation and OS. According to Tahan
et al. [109], 100 mg/kg.bw/d MEL i.p. for 3 days in mice, decreased
ROS synthesis, by inhibition of colonic MPO activity, as well as
RONS damage by decrease of MDA colonic levels. In this study,
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GSH levels and colonic SOD activity. In a study using mice con-
ducted by Trivedi et al., a lower dose of MEL was tested: 1 mg/kg.
bw/d MEL for 8 and 18 weeks, after colitis induction by dextran
sulfate sodium (DSS). This treatment caused a signiﬁcant decrease
in the levels of inﬂammatory and oxidative colonic markers: MPO
activity, COX2, signal transducer and activator of transcription 3
(STAT3) and NF-kB colonic expression, TBARS colonic levels and
DNA damage [104].
Changes in MEL metabolism was also observed in patients with
UC. These changes are related to the severity of the disease, and
according to [110], adjuvant MEL therapy may help in sustaining
remission in patients with UC. Although none of these studies has
evaluated OS, the potential beneﬁt of MEL is clear. New trials to
analyze the antioxidant effect of MEL are needed.
3.3.1.4. Synthetic substances. A synthetic substance (pro-drug)
with various antioxidant effects on colitis is N-acetylcysteine or
NAC (Fig. 2). It acts as a cysteine prodrug and a GSH precursor
[111]. Being a thiol (R-SH), it can be oxidized by various radicals
and also serve as a nucleophile [111]. NAC is an artiﬁcial anti-
oxidant that has shown positive results in both IBD animal models
[112] and clinical trials [113], in addition to being used with suc-
cess in the treatment of several disorders, such as intoxication
[111], cardiac ischemia-reperfusion [114], chronic obstructive pul-
monary disease (COPD) [115], bronchitis [116], HIV/AIDS (Human
Immunodeﬁciency Virus/Acquired Immunodeﬁciency Syndrome)
[117], psychiatric disorders [118] and diabetes [119].
Antioxidant capacity reduction in a cellular environment is
mainly due to a decrease of GSH and/or increased oxidized glu-
tathione (GSSG) [116]. GSH depletion has been observed in both
IBD patients and different models of colitis induction [120]. NAC
increases antioxidant defense activity by providing cysteine, which
is required for GSH synthesis. Furthermore, NAC decreases OS by
RONS (HO, NO2) scavenging, along with carbonate radical
(CO3–) [111] and metal chelation (Cuþ2, Feþ3, Cd2þ , Hg2þ and
Pb2þ) which are metals involved in ROS generation and in the
inﬂammatory response [121].
The anti-inﬂammatory and antioxidant activities of NAC have
also been conﬁrmed through observation of NF-kB inhibition [89].
This antioxidant activity may contribute to the therapeutic effects
of NAC on IBD. According to [120], oral NAC (150 mg/kg bw/d) for
45 days along with 3 DSS cycles, generated a moderate impact on
colonic oxidation of lipids and proteins, decreased colonic MPO
and NO serum levels, and improved colon antioxidant status by
increasing GSH and CAT activities, suggesting that a long term NAC
diet might be beneﬁcial for IBD.
Within the category “synthetic antioxidants and chemicals
derived from sources, other than vegetables”, we found substances
naturally produced by human body or other non-probiotic alive
organisms. Here, it stands the real therapeutic possibility of
modiﬁed SOD and propionyl-L-carnitine (PLC) (Fig. 2), both already
in clinical trial phase due to their high therapeutic power, however
in this review, during the search period, there was no evaluation of
OS markers (Table 1).
Due to its signiﬁcant ROS scavenging ability, great interest has
been focused on SOD, for therapeutic use. However, because of
extremely rapid plasma clearance time, instability, and im-
munogenicity in vivo, the clinical application of SOD as a ther-
apeutic agent has been very limited [122]. Several attempts to
obtain active and stable SOD have been tested successfully in lung
inﬂammation [123] as well as for IBD treatment. Inshihara et al.
utilized a lecithinized human Cu/Zn–SOD (PC–SOD), in which four
phosphatidylcholine-derived molecules were covalently bound to
each SOD dimer. These authors observed, using inﬂammatory
markers, that PC–SOD, administered intravenously (i.v.), decreasedboth MPO activity and phospho-NF-κB p65 [124]. In fact, admin-
istration of PC–SOD (40 mg/kg/d) for 14 days, had shown a safe
and beneﬁcial effect on UC-Disease Activity Index (DAI) [125].
Another modiﬁed SOD applied to IBD treatment was Lactoba-
cillus fermentum, a recombinant superoxide dismutase (rec-SOD).
This rec-SOD was able to improve redox imbalance by increasing
oxidative defense (SOD colonic activity), decreasing ROS damage
(LP) and as noted by [124] using PC–SOD, rec-SOD also reduced
MPO, as well as NF-κB p65 expression in the colonic tissue [126],
both in animal models.
Propionyl-L-carnitine (PLC), a natural ester derivative of L-car-
nitine that acts as an antioxidant molecule, is reduced in the ser-
um of UC patients, suggesting that this molecule can serve as a
source of L-carnitine, which plays an essential role in energy
metabolism, since it transports activated long-chain fatty acids
into the mitochondrial matrix, for β-oxidation [126]. In a phase II
trial, PLC caused decreased symptoms (pain and rectal bleeding) in
UC patients, compared to a placebo group [127]. Unfortunately,
this multicentric trial did not investigate OS markers, and for that,
they are not in our review. But it is possible to infer that, as
identiﬁed by Scioli et al. [128], PLC can be an important scavenger
and synthesis inhibitor of ROS, since classic IBD symptons have OS
involved in the pathogenic process. These studies using experi-
mental models and further studies in patients with UC contribute
to a fundamental basis for its clinical use as a safe therapeutic
alternative, but determination of safe doses and long-term studies
are still necessary to ensure its correct prescription by health
professionals.
3.3.2. Polyphenols and other natural active compounds of medicinal
plants
Polyphenols or phenolic compounds refer to a broad group of
molecules found mainly in plants that are characterized by the
presence of one or more phenyl rings and one or more hydroxyl
groups linked directly to the aromatic rings. They can be classiﬁed
into ﬁve structural groups: phenolic acids, ﬂavonoids, anthocya-
nins, stilbenes and lignans. A growing body of evidence indicates
that polyphenols are health-promoting phytochemicals [129].
They possess antioxidant properties, acting directly as free-radical
scavengers or indirectly by interfering with speciﬁc proteins in the
redox signaling pathways that are involved in different biological
functions [33].
Pure polyphenol standards can interfere with the induction of
NF-kB and MAPKs signaling pathways in intestinal cells. Most of
the studied polyphenols exhibited anti-inﬂammatory behavior by
inhibiting the activation of the NF-kB cascade [130]. Furthermore,
some polyphenols have been shown to have other functions,
speciﬁcally in relation to the intestinal barrier (Table 1). In a study
by Shigeshiro et al. [131], on experimental colitis, the adminis-
tration of polyphenols: curcumin, quercetin, naringenin or he-
speretin led, collectively, to restoring DSS-induced colitis, at least
in part, through regulation of the colonic and tight junction (TJ)
barriers. As described in the legend of Fig. 4, intercellular junctions
are one of the mechanisms that provide intestinal integrity and
RONS can promote disruption of these structures, by increasing
intestinal permeability with neutrophil and bacterial/toxin in-
ﬁltration, and by the inﬂammatory process [46,132]. Although
Shigeshiro et al. [131] did not demonstrate a direct relationship
between the use of polyphenols and OS, it is understood that these
components may reduce the harmful action of ROS on the in-
testinal mucosa.
3.3.2.1. Resveratrol. Among the polyphenols, one of the most ex-
tensive and commonly studied is the resveratrol-based class
(Fig. 2). These compounds are widely distributed in all foods of
plant origin such as red grapes, in certain berries, and in peanuts. A
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its low bioavailability, due to its rapid absorption and metabolism
in the extensive upper gastrointestinal tract and liver. In order to
improve its use for the treatment of this disease, a resveratrol-
colon-speciﬁc drug delivery system was designed to overcome its
poor solubility, limited stability, high metabolization in the upper
gastrointestinal tract with increased efﬁcacy, restoring enzymatic
and nonenzymatic antioxidant defense, and decreased adverse
effects [133,134]. However, one of the 41 papers found is a pilot
study [135], which observed important antioxidant and anti-in-
ﬂammatory effects on the activity of plasmatic NF-κB, conﬁrming
that this polyphenol is able to attenuate UC activity and may act,
also, as an anticancer agent [136].
Abdin investigated the use of a colon-speciﬁc delivery of re-
sveratrol in rats with colitis and observed a decrease in colonic
MPO activity [137). Similar results were observed for trans-re-
sveratrol in studies by Larrosa et al. [138] and Yao et al. [139]. In
addition, [140] reported additional antioxidant and anti-in-
ﬂammatory effects of trans-resveratrol as observed by decreased
COX1 and COX2 enzymes. Other markers for OS were improved
after resveratrol use, such as decrease of colonic expression of
iNOS and NF-kB in addition to MDA and colonic MPO levels [141–
143].
Despite these promising results, the resveratrol dosage capable
of maximizing health beneﬁts without raising toxicity problems
remains an area of controversial debate [144]. In fact, several
studies have demonstrated that resveratrol can have a potent non-
speciﬁc toxicity toward normal cells, particularly endothelial cells
with a low oxidative condition. Resveratrol, in high concentration,
had been recognized as a dangerous compound rather than as an
antioxidant, by its metabolization through anti-xenobiotic en-
zymes, thus producing ROS [145]. As such, this evidence conﬁrms
the necessity for determining optimal doses of resveratrol to
maintain the health of individuals.
3.3.2.2. Curcumin. Curcumin (Fig. 2), a hydrophobic polyphenol, is
the major representative of curcuminoids, the main chemical
constituents of the spice turmeric, and in curry powder. Turmeric
is prepared from the root of the plant Curcuma longa, a member of
the ginger family. It is native to India and Southeast Asia and has
been used to treat a broad range of common ailments, especially
inﬂammatory diseases, as an oral and topical medicine, in Indian
Ayurvedic medicine for at least 4000 years, as well as in Chinese,
Arabic and other traditional medicines [146]. Its beneﬁcial effects
on IBD were observed in animal models [147], through in vitro
assays [148] and clinical trials [149,150]. The main effects attrib-
uted to curcumin are related to anti-inﬂammatory and anticancer
activities [136], however in analyzing Table 1, we can observe that
curcumin, alone [151,152], or in combination with other plants
such as Gingko biloba [153] or compounds like aminoguanidine
[154], show important antioxidant effects, like decrease of LP, and
of RONS production, as well as increase of antioxidant enzymes.
These results conﬁrm that curcumin is a potential new treatment
for IBD.
3.3.2.3. Quercetin. Quercetin (Fig. 2) was able to prevent oxidative
injury and cell death by various mechanisms, for instance, as a ROS
scavenger, an iron chelator [155] and an endogenous antioxidant
(GSH) modulator [156]. It has been reported that quercetin plays
an important role in cell cycle kinetics and proliferation and in-
duction of apoptosis in cell culture [157]. Quercetin antioxidant
capacity includes the most potent ROS, among them O2-, HO,
RO2, RO, and reactive nitrogen species like NO and ONOO–.
According to its properties, [155] tested different orally adminis-
tered doses (50 and 100 mg/kg.bw/d) for 10 days in TNBS (trini-
trobenzene sulfonic acid)-colitis. In this study, both therapeuticdoses signiﬁcantly attenuated colonic MPO activity, MDA levels
and serum NO levels, while increasing the colonic levels of GSH.
[156] evaluated the therapeutic effect and mechanisms of orally
administered quercetin in microcapsules (100 mg/kg bw/d) on
acetic acid-induced colitis. This microencapsulated form reduced
MPO, increased GSH colon levels and presented an elevated anti-
oxidant capacity evaluated through FRAP (Ferric Reducing Anti-
oxidant Power).
In addition to their direct antioxidant action, some poly-
phenols, like quercetin, act in maintaining the intestinal barrier
function by selective protein kinase C δ (PKCδ) inhibition, result-
ing in the promotion of occludin phosphorylation of TJ (tight
junctions) assembly [158]. Although the precise mechanism un-
derlying the quercetin mediated promotion of TJ protein assembly
and expression remains unsolved, it is clear that this ﬂavonoid
induced the phosphorylation of occludin in human cell cultures
concomitantly with the assembly of the TJs [159].
3.3.2.4. Catechin class. Another important polyphenols derived
from the green tea, especially in the (–)-epi-gallocatechin-3-gallate
(EGCG) fraction (Fig. 2), which represents up to 30% of the dry
weight of green tea leaves [160]. Green tea is one of the most
popular beverages consumed worldwide, being second, next to
water. Although green tea consists of 42000 components, inter-
est has focused on the polyphenols which include EGCG, (–)-epi-
gallocatechin (EGC), (–)-epi-catechin gallate (ECG) and (–)-epi-ca-
techin (EC) (Fig. 2), all of which have potent antioxidant properties
[161].
In order to improve bioavailability, stability, and cancer pre-
ventive activities of EGCG, per-acetylated EGCG (AcEGCG) was
synthesized by [162] and tested in colitis by [163]. According to
these authors, dietary consumption of AcEGCG demonstrated to be
more effective than EGCG in preventing DSS-induced colitis. The
antioxidant action of EGCC can be explained by several mechan-
isms, including activation of Nrf2 signaling. Despite this, none of
the studies evaluated the effect of EGCG on enzymatic expression
or activity. EGCG, like quercetin, improved intestinal TJ barrier
dysfunction. However, the molecular mechanisms underlying
these EGCG-mediated effects remain unclear [131].
Three papers evaluated the effect of grape seed proanthocya-
nidines (GSPs) on induced UC. GSPs contain approximately 89%
proanthocyanidins, with dimers (6.6%), trimers (5.0%), tetramers
(2.9%) and oligomers (74.8%) [164]. The antiproliferative, anti-
oxidant, and anticarcinogenic effects of GSPs can be explained,
principally, by their action on decreasing expression of NF-κB
targeted genes [85,165,166]. According to Ref. [165], it is possible
to consider that GSPs suppress IκK (inhibitor of κB kinase) acti-
vation, and the inactivated IκK complex suppresses the phos-
phorylation-induced degradation of IκBα (IκB kinase α). GSPs
were also able to increase colonic SOD activity [85,166], conﬁrm-
ing their antioxidant effect on improving enzymatic defense.
3.3.2.5. Others. Myricetin, narigenin, kolaviron and amentoﬂavone
(Fig. 2) were also successfully, used for IBD (animal model). These
substances were tested by oral [167–169] or i.p. [83] administra-
tion. Independently of routes, most ﬂavonoids exhibited free ra-
dical scavenger ability, particularly toward NO [155,170–172],
reduced lipid peroxidation [83,155,170–172], promoted an in-
crease in antioxidant defense, principally through SOD activity
[83,155,170–172] and GSH levels [83,155,156,171]. In analyzing
these results, the potential therapeutic use of ﬂavonoids becomes
evident. However, it should be pointed out that they concurrently
have pro-oxidative properties, which have some associations with
potential toxicity [173]. Furthermore, because this antioxidant
power has only been tested in animal models, clinical trials are
necessary to determine the ﬂavonoid efﬁcacy not only in the acute
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better quality of life for IBD patients.
Other natural substances with antioxidant power had been
identiﬁed in plants. A recent meta-analysis carried out on herbal
therapy in humans concluded that herbal medicines may safely
induce clinical response and remission in patients with IBD (his-
tological index and adverse event) [174], however no parameter
observed was related to OS. Furthermore, neither extract nor
natural compound has been so far recommended by the Interna-
tional Society of Nutritional Therapy as adjuvant therapy for IBD
[175,176].
In this review, 21 active compounds were identiﬁed and tested
in IBD therapy (Table 1), all of them in animal models. The pig-
ment indicaxanthin (Fig. 2) [177], which antioxidant activity in
vitro, involves reduction of the expression of COX-2 and iNOS as-
sociated to inhibition of NF-κB activation, and consequently in-
hibition of RONS synthesis and scavenging of NO and ROS, stands
out. The alkaloid berberine [178] obtained from the rhizome of
Coptidis japonica and the stem bark of Mahonia aquifolium, which
antioxidant action in TNBS-induced experimental colitis involves
reduction of RONS synthesis (decreasing expression of COX2 and
iNOS and MPO activity) plus decrease of MDA levels, stimulation of
SOD and CAT activities and increase of GSH content is also no-
ticeable. The active compounds of Cannabis sativa, cannabigerol
[179] and cannabidiol [180] (Fig. 2), which present non-psycho-
thropic actions and in face of their antioxidant activities such as
scavenger of RONS and decrease of iNOS expression, may stimulate
future studies.
Despite different alterations identiﬁed for antioxidant defense,
the active compounds utilized in IBD treatment were able to im-
prove redox imbalance, reducing the levels or activity of OS when
the antioxidant was increased and vice versa.
Thus, identiﬁcation and characterization of novel anti-in-
ﬂammatory and antioxidant components of plants may aid in
improving current nutritional formulas. In face of this evidence, it
is feasible to assert that herbal therapy shows beneﬁcial results for
both inﬂammation and OS, in animal models.
3.3.3. Functional foods, antioxidant nutrients and probiotics
The impact of functional foods on the course of IBD has been
examined for a small number of speciﬁc dietary factors (Table 1)
[181].
3.3.3.1. Camel's milk. Camel's milk (CM) might represent a poten-
tial candidate for pharmacological efﬁcacy on IBD with minimal
adverse reactions [31]. It is different from other ruminant milk,
due to its high content in minerals (calcium, iron, magnesium,
copper and zinc), vitamins (A, B2, C and E) and insulin, and lower
content in fat, cholesterol, protein and sugar [182]. It also contains
a relatively large amount of polyunsaturated fatty and linoleic
acids, which are essential for human nutrition [183]. With regard
to the high risk of malnutrition in the course of IBD, nutritional
support plays a crucial role in the management of these patients.
CM has been consumed as an essential nutritional supplement
with high energy and vitamin content to help immune-deﬁcient
patients [31]. Malabsorption syndrome has been identiﬁed as
potential trigger for symptoms of IBD, such as abdominal pain,
bloating and distension, altered bowel habits and malnutrition
[184,185].
Besides having antioxidant properties, CM is rich in lactoferrin,
a protein with marked antioxidant and anti-inﬂammatory prop-
erties [186]. In view of these properties, Arab et al. evaluated the
effects of CM (10 mL/kg.bw/d by gavage, one week before colitis
induction (c.i.) and at the 4th day post c.i.) against TNBS-induced
colitis in rats. Attenuation of colon injury was observed through
suppression of OS via reduction of lipid peroxides (MDA), NO andMPO activity along with boosting of the antioxidant defenses
through restoration of colonic GSH and total antioxidant capacity
(TAC) [31].
More studies are necessary to investigate if CM may be a va-
luable complementary approach for the management of IBD.
3.3.3.2. Extra virgin olive oil. Another functional food that may
exhibit beneﬁcial effects on IBD without undesirable effects that
accompany the classical pharmacotherapy is extra virgin olive oil
(EVOO) [187]. It is a typical ingredient in a Mediterranean diet. It is
obtained from the fruit of the olive tree solely by mechanical or
other physical means under conditions that do not lead to alteration
of the oil [188]. EVOO could modulate responses against OS, for all
antioxidant enzymes and consequently attenuate IBD [189]. EVOO
consumption increases the activity of antioxidant enzymes such as
CAT, SOD and GPX [190]. The protective role of EVOO is the result of
its speciﬁc composition including high proportions of mono-un-
saturated fatty acids (oleic acid), a balanced presence of poly-
unsaturated fatty acids and other minor components, such as α-
tocopherol and phenolic compounds [191], such as simple phenols
(hydroxytyrosol, tyrosol), aldehydic secoiridoids, ﬂavonoids and
lignans (acetoxypinoresinol, pinoresinol) [187].
Previous studies have shown that patients with IBD are among
the highest risk groups for developing colon-rectal cancer (CRC)
[192]. Experimental studies have indicated a role of dietary lipids
on cancer, particularly in colon tumor development. For instance,
it was demonstrated that high fat diets rich in ω-6 poly-
unsaturated fatty acids and saturated fatty acids promote carci-
nogenesis, while high fat diets rich in ω-3 fatty acids had a pro-
tective effect [193,194]. Considering that chronic inﬂammation is
the key predisposing factor to CRC in IBD, [195] evaluated an EVOO
diet (5%) in DSS-induced colitis for 5 weeks. In these animals,
suppression of COX2 and iNOS colonic expressions was observed.
COX2 is expressed in response to growth factors (transforming
growth factor α), pro-inﬂammatory cytokines (interleukin 1α)
[196], while iNOS produces large amounts of NO which is im-
plicated in initiation, promotion and progression of tumors [197].
This study indicates that chronic feeding of a 5% olive oil diet for
5 weeks attenuates inﬂammation in DSS-induced colitis of rat
colons, based on evaluations using COX2 and iNOS [195].
As already shown, phenolic compounds are recognized as
holders of important antioxidant, anti-inﬂammatory, anti-
microbial, antiproliferative, antiarrhythmic, platelet antiaggregant
and vasodilatory effects, as well as able to modulate important
cellular signaling pathways [188,198]. EVOO has remarkable anti-
oxidant potential derived from its high level of phenolic com-
pounds [189]. Sánchez-Fidalgo et al. [199] investigated the effects
of an EVOO diet enriched with its principal polyphenols-hydro-
xytyrosyl acetate (HTy-Ac) and 3,4-dihydroxyphenylglycol (DHPG)
(Fig. 2) (both at 0.1% for 30 d before c.i.) on the severity of DSS-
induced acute inﬂammation. Only the HTy-Ac supplemented
group showed a reduction in COX2 and iNOS colonic protein ex-
pression. Furthermore, in DSS-treated mice, supplemental HTy-Ac
blocked the activation of the NF-kB pathway and boosted anti-
oxidant defenses through the decrease of MPO colonic activity,
and reduction of the degree of polymorphonuclear neutrophils
inﬁltration [199].
Given the few experimental studies performed, addressing the
protective activity of olive oil on colon cancer and the anti-in-
ﬂammatory and antioxidant properties of the compounds present
in EVOO, further experimental and clinical studies are needed to
investigate whether olive oil intake and its doses are effective to
attenuate OS and inﬂammation in UC.
3.3.3.3. Micronutrients. Some micronutrients found in food, such
as α-tocopherol or vitamin E and ascorbic acid (vitamin C), act as
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tioxidants or antioxidants administered as supplements are ap-
plied on a large scale in an attempt to alleviate ROS induced da-
mage such as apoptosis, alteration in immune response modula-
tion and innate immunity, and others [200].
Vitamin E is the blanket term that covers all biologically active
tocopherols and tocotrienols and their derivatives. Numerous
beneﬁcial health effects have been proposed for vitamin E, which
are attributed to its antioxidant activity [201]. Additionally, vita-
min E is associated with a reduced risk of coronary heart disease
[202] and colon cancer [203].
Chemically, vitamin E is a lipid-soluble vitamin, which is bio-
logically active in tissues and plasma. Tocopherols, therefore,
protect lipid membranes by quenching/scavenging singlet oxygen
(and potentially also other ROS, such as HO) [204]. Despite the
beneﬁcial action of vitamin C, which can contribute to vitamin E
regeneration [205], in vivo studies have demonstrated contra-
dictory results when this vitamin is combined with other anti-
oxidants. According to [206], vitamin E, vitamin C and lipoic acid
protect the arachidonic acid level in the brains of diabetic and
non-diabetic rats. However, when a combination of high doses of
vitamin E with oxidized sunﬂower oil is used, this vitamin pre-
sents pro-oxidant action [207].
The major impediment to vitamin E use in the treatment of
acute inﬂammatory diseases such as UC, is its low solubility in
water, preventing its oral ingestion or enema administration in
patients. Therefore, the use of derivatives of vitamin E such as
tocopheryl acetate and α-tocopheryl phosphate, which are more
water soluble [208], have been preferred as dietary supplements.
α-Tocopherol was utilized alone [47] and in combination with
other nutrients [209,210]. Interestingly, the results had shown an
absence of colonic antioxidant effect, when vitamin E was utilized
with vitamin C and GSH [210]. Some meta-analyses have shown
that antioxidant supplements do not result in the presumed health
beneﬁt, but paradoxically a high intake of antioxidants is asso-
ciated with increased mortality [211,212]. Those observations
suggest a pro-oxidant effect of antioxidants and it seems that this
deleterious effect is associated to Nrf2 mutations [213].
Other nutrients relevant to the maintenance of intestinal
homeostasis are selenium (Se) and zinc (Zn), essential elements
for the restructuring of antioxidant enzymes such as GPx and SOD.
Selenium interacts with the active site of GPx, which is essential to
combat ROS and to regenerate adipocytes by reacylation. On the
other hand, zinc as a SOD cofactor is indirectly involved with
oxidant defense. When this mineral was used in combination with
vitamin E [209] or anti-TNF-α (a drug preconized for the treatment
of CD) [214], an improved redox balance was observed in plasma
and/or colonic tissue (Table 1).
Aghdassi et al., in 2003 [215], conduced the ﬁrst randomized
controlled trial on antioxidant (Vitamins C and E) on CD. These
authors observed an important decreased of oxidative damage
(reduction of LP in plasma) in patients, which received the sup-
plementation for 4 weeks, versus placebo group. More recently, in
2008, Roggenbuck et al. [216] studied six patients with CD which
received a nutritional formulation containing several antioxidants
(Vitamin C, vitamin E, β-carotene, zinc, selenium and glutamine)
for 4 weeks. According to those authors, this supplementation was
not sufﬁcient to improve oxidative stress and inﬂammatory bio-
markers, but increased antioxidant status of plasma and inﬂamed
mucosa. Thereby, they concluded that supplementation was in-
conclusive and stimulated to continuation this therapeutic ap-
proach in placebo-controlled trials.
From these results, it is fundamental before prescribing anti-
oxidant nutrients, to understand that each antioxidant has its own
unique biochemical proﬁle and therefore antioxidants should not
be treated as a group [201].Recently, an interesting review conducted by Di Stasi and Costa
[217] evaluated patent literature focused on chemical compounds,
functional foods and biological therapy useful for the treatment of
IBD. The paper selected 33 patented products during the period
2013–2014 and just one of themwas included in this review, lipoic
acid. However, the authors were critical about the quality of those
patents, once most of them are not conclusive because they were
based on data from unspeciﬁc methods that are not related to
intestinal inﬂammation. Besides that, clinical studies have rarely
been described in patients, strongly limiting their evaluation and
medical applicability.
3.3.3.4. Probiotics. In recent years, a rising interest in the hypoth-
esis that gut dysbiosis can result in immune impairment effects
associated with IBD, resulted in several studies on probiotics and
prebiotics. Probiotic bacteria may be deﬁned as live microorgan-
isms which, when administered in adequate amounts, confer a
health beneﬁt on the host [169].
The antioxidant action of probiotics can be due to ROS
scavenging, metal ion chelation, enzyme inhibition, and the re-
duction and inhibition of the ascorbate autoxidation [218,219], as
well as the synthesis of antioxidant enzymes by bacteria used in
the formulas [220]. Probiotic antioxidant power had been de-
monstrated in healthy subjects by increased Total Antioxidant
Activity – TAA – and Total Antioxidant Status – TAS [221], in car-
diovascular disease, by decreased ROS production [222], and in
non-alcoholic fatty liver disease in children, as shown in a review
by Yang et al. [223].
In a recent in vitro and in vivo study, using Lactobacillus and
Biﬁdobacterium conducted by Amaretti et al., the authors identiﬁed
that given the colon colonization by administered probiotics, it is
conceivable that their overall protective effect could be related to
activities taking place at the intestinal level, i.e., secretion of en-
zymes like SOD, metal-chelating activities, promotion of the pro-
duction of antioxidant biomolecules such as exopolysaccharides
that had shown in vitro antioxidant and free-radical scavenging
activities [224].
Even it a speciﬁc pathogen has not yet been identiﬁed as an
etiopathogenetic factor and a deﬁnite infectious cause cannot be
considered alone, the involvement of gut microbiota in the pa-
thogenesis of these diseases is generally recognized [225]. Several
studies in UC patients have demonstrated anti-inﬂammatory ef-
fects and improvement of clinical markers as a result of probiotics
use, in particular E. coli Nissle 1917, VSL#3, Lactobacilli and/or Bi-
ﬁdobacteria [169]. However, for CD, there have been no beneﬁts
that would recommend their use [226].
Although few studies (Table 1), and all in animal models, have
investigated antioxidant action by probiotics, these microorgan-
isms have been shown to increase SOD, CAT and GPx activity
[220,227], GSH levels [227], as well as to reduce MPO [228] and
NO [229] activity. However, a noticeable result was reported by
Gardlik et al., who used recombinant probiotics. According to
these authors, despite the lack of increase in MDA levels and ad-
vanced oxidation protein products in colitis induced by the DSS
group, administration of all E. coli strains lowered these para-
meters, when compared to the control group [230].
This result suggests a potential antioxidant action caused by
probiotics and the daily use of 200 mg of E. coli Nissle 1917 (Mu-
taﬂor) may be an option for UC patients who are unable or un-
willing to take mesalazine, as recognized by the British Society of
Gastroenterology [231]. However, one of the difﬁculties found in
this review, regarding this nutraceutical, was the diversity of
bacterial strains and therapeutic doses used.
Jonkers et al. conducted a systematic review about probiotics in
management of IBD and concluded that future studies should fo-
cus on speciﬁc disease subtypes and disease location [232].
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possibilities of probiotics for IBD, including their antioxidant
power.4. Conclusions and future perspectives
Alternative therapies for IBD are a vast ﬁeld of scientiﬁc inter-
est. In this systematic review, 101 different substances/live or-
ganisms/functional foods with antioxidant capacity, principally for
UC, were identiﬁed. However, few compounds were tested more
than once, including: the angiotensin II receptor antagonist
[99,100,233]; the inhibitors of hydroxymethylglutaryl COA re-
ductases [101]; the hormone MEL [96,103,109,234]; the synthetic
substances N-acetylcysteine [120,235–238], bis(1-hydroxy-2,2,6,6-
tetramethyl-4-piperidinyl)decandioate [239,240] and 3,4-oxo-iso-
propylidene-shikimic acid [241–243]; resveratrol, some of its de-
rivatives [137,138,140–143,244] and curcumin [151–154]; the ﬂa-
vonoids proanthocyanidin from grape seeds [85,165,166]; quer-
cetin [155,156]; coumarin derivatives [76,245,246]; the microalga
spirulina [247,248]; active compounds such as cannabigerol [179]
and cannabidiol [180] from Cannabis sativa [179,180], which
hampered the performance of a meta-analysis.
Several OS biomarkers were employed in all the papers, in
particular: NO, the pro-oxidant enzymes MPO and COX2, the
transcriptor factor NF-kB; antioxidant enzymes SOD, CAT, GPx and
the non-enzymatic antioxidant compound GSH or the ratio GSH/
GSSG. This chemical diversity contributes to the understanding of
the metabolic pathways. However, only few studies analyzed Nrf2
expression [11,55,96,104] and, in view of its strong association
with redox imbalance and inﬂammation, as discussed previously,
the regulation of Nrf2-ARE signaling may be closely linked with
pharmacological intervention. Thus, the knowledge of the me-
chanism and consequent control of these redox-dependent events
where the tested substances are used can provide us with alter-
natives to attenuate inﬂammatory-mediated diseases at the mo-
lecular and metabolic level.
Besides the role of OS in IBD etiology, the consistent increase of
RONS have an important action in the recurrence of the active
phase (Fig. 1) and consequently the use of antioxidants may help
in the maintenance of remission phase [36].
According to Piganelli & Delmastro (2011), optimal treatments
may have to incorporate antioxidants together with anti-in-
ﬂammatory agents, such as NFκB activation inhibitors, and must
also take into consideration the limitations associated with the use
of intact enzyme/protein therapies, such as bioavailability, im-
munogenicity-limited cellular accessibility, and the cost of pro-
duction [249]. In this context, functional foods and natural active
compounds of plants ﬁt very well for the treatment of IBD
In vitro and in vivo preclinical models, like the ones cited in the
review, are fundamental to conﬁdently test several isolated com-
pounds/extracts/nutraceuticals/hormones/foods, before human
trials. This fact partially explains why only two papers, based on
the criteria adopted (OS markers), reported the use of compounds
in humans subjects: resveratrol [135], extract pycnogenol in chil-
dren [250] and antioxidant nutrients [215,216]. Others were per-
formed and included in the present review, but could not enrich
the statistics, once OS markers were not assessed.
It is clear that more research is necessary in order to implement
the use of these compounds/drug/foods/synthetic substances, thus
paving the way for new therapeutic possibilities to be brought to
millions of IBD patients. Studies regarding pharmacokinetic para-
meters and metabolic proﬁles are essential and are normally the
ﬁrst approach in clinical trials [311].
It is essential that the same substance is tested several times in
various conditions (acute, chronic, recidive, and CHC) and indifferent models before being tested in humans.
It is strongly desirable that research on IBD and their etiology
or triggering factors in humans involves OS markers, because it is
clear that this phenomenon is crucial to the onset of inﬂammation
and that this, in turn, is directly related to the aggravation of the
disease, by a concomitant formation of RONS. Until these issues
are fully understood, in the fundamental and molecular levels, in
terms of pharmacokinetics and metabolism, health professionals
should assess individually the prescription of these substances/
natural or synthetic compounds is valid for their patients with IBD.
However, actually, in face of all results, the alternative antioxidant
therapy to IBD seems promising and must be further and con-
tinuously investigated, especially, in clinical trials.Acknowledgments
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